Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Recent & Breaking News (OTCQB:PVCT)

Provectus Biopharmaceuticals Awarded Patent Extending Protection of the PV-10 Manufacturing Process

Business Wire March 1, 2016

Provectus Biopharmaceuticals to Host Business Update Conference Call Tuesday, March 1, 2016, at 4 PM EST

Business Wire February 29, 2016

Provectus Biopharmaceuticals Initiating Phase 1 Study of PV-10 in Neuroendicrine Tumors Metastatic to Liver

Business Wire February 29, 2016

Provectus Biopharmaceuticals Announces Leadership Changes

Business Wire February 29, 2016

Provectus Biopharmaceuticals Announces Data on PV-10 and Co-Inhibitory Blockade to Be Presented at American Association for Cancer Research Annual Meeting 2016

Business Wire February 24, 2016

Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Thursday, March 10, 2016, at 4 PM EST

Business Wire February 10, 2016

Data on Immunology Effects of Provectus Biopharmaceuticals PV-10 in Colon Cancer Presented at 11th Annual ASC Meeting

Business Wire February 3, 2016

Provectus Biopharmaceuticals to Present at 18th Annual BIO CEO & Investor Conference

Business Wire February 2, 2016

Provectus Biopharmaceuticals Announces Immunology Data on PV-10 in Colon Cancer to Be Presented at 11th Annual ASC Meeting

Business Wire January 22, 2016

MicroCap Review Magazine Winter/Spring 2016 Issue Now Available

Marketwired January 19, 2016

Provectus Biopharmaceuticals Confirms First Patients Dosed in Trials of PV-10 for Melanoma

Business Wire January 12, 2016

Provectus Biopharmaceuticals, Inc. to Present at Biotech Showcase(TM) 2016 on Wednesday January 13, 2016 at 3:30 PM Pacific Time

Business Wire December 16, 2015

Provectus Biopharmaceuticals Reports Immune Mechanism of Action Data for Pv-10 Presented at Society for Immunotherapy of Cancer Annual Meeting Authored by Researchers at Moffitt Cancer Center

Business Wire November 5, 2015

Provectus Biopharmaceuticals Reports Third Quarter 2015 Financial Results

Business Wire November 5, 2015

Provectus Biopharmaceuticals Will Hold Its 2015 Third Quarter Business Update Conference Call on Thursday, November 5, 2015, at 5 PM Eastern Standard Time

Business Wire October 20, 2015

Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 Tumor Ablation and Immune Stimulation

Business Wire September 29, 2015

Provectus Biopharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial to Study PV-10 in Combination with Immune Check Point Inhibitor Pembrolizumab

Business Wire September 23, 2015

Provectus Biopharmaceuticals Completes Patient Accrual for PH-10 Phase 2 Clinical Study of Cellular and Immunologic Changes in the Skin

Business Wire September 21, 2015

Point Capital Quarterly Update

GlobeNewswire September 3, 2015

Provectus Biopharmaceuticals Awarded US Patent Protecting Use of PV-10 as Part of Combination Therapy for Cancer

Business Wire August 18, 2015